View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2013	Oct. 31, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Current Fiscal Year End Date	--12-31
Trading Symbol	stxs
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		15,935,157

Balance Sheets - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 8,386,605	$ 7,777,718
Accounts receivable, net of allowance of $301,459 and $640,183 in 2013 and 2012, respectively	8,096,385	11,570,489
Inventories	4,738,032	5,098,241
Prepaid expenses and other current assets	1,918,412	3,492,067
Total current assets	23,139,434	27,938,515
Property and equipment, net	1,419,320	2,141,923
Intangible assets, net	1,754,445	1,979,320
Long-term receivables	19,975	73,199
Other assets	33,815	32,987
Total assets	26,366,989	32,165,944
Current liabilities:
Short-term debt and current maturities of long-term debt	3,242,800	12,264,490
Accounts payable	3,193,816	3,556,688
Accrued liabilities	6,839,797	5,361,810
Deferred revenue	7,399,431	9,502,939
Warrants and debt conversion features	4,955,588	2,968,348
Total current liabilities	25,631,432	33,654,275
Long-term debt, less current maturities	18,242,083	16,824,736
Long-term deferred revenue	293,047	477,159
Other liabilities
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2013 and 2012
Common stock, par value $0.001; 300,000,000 shares authorized, 15,925,480 and 8,018,615 shares issued at 2013 and 2012, respectively	15,925	8,019
Additional paid in capital	431,831,756	366,053,627
Treasury stock, 4,015 shares at 2013 and 2012	(205,999)	(205,999)
Accumulated deficit	(449,441,255)	(384,645,873)
Total stockholders' deficit	(17,799,573)	(18,790,226)
Total liabilities and stockholders' deficit	$ 26,366,989	$ 32,165,944

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 301,459	$ 640,183
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	15,925,480	8,018,615
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	3 Months Ended		9 Months Ended
Statements Of Operations - USD ($)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:
Systems	$ 4,449,598	$ 5,040,025	$ 10,000,926	$ 14,082,637
Disposables, service and accessories	6,371,846	6,521,374	18,962,129	20,274,888
Total revenue	10,821,444	11,561,399	28,963,055	34,357,525
Cost of revenue:
Systems	2,338,175	2,429,764	5,132,007	6,948,145
Disposables, service and accessories	1,161,449	1,057,057	3,032,150	3,560,585
Total cost of revenue	3,499,624	3,486,821	8,164,157	10,508,730
Gross margin	7,321,820	8,074,578	20,798,898	23,848,795
Operating expenses:
Research and development	1,300,287	1,904,648	4,313,590	6,925,928
Sales and marketing	4,102,968	4,096,842	13,213,528	16,318,911
General and administrative	2,987,408	3,007,598	9,688,116	10,349,817
Total operating expenses	8,390,663	9,009,088	27,215,234	33,594,656
Operating loss	(1,068,843)	(934,510)	(6,416,336)	(9,745,861)
Other income (expense)	(48,160,084)	598,494	(46,660,340)	9,679,848
Interest income	1,306	1,982	3,973	5,353
Interest expense	(7,640,821)	(1,581,247)	(11,722,679)	(4,861,106)
Net income (loss)	$ (56,868,442)	$ (1,915,281)	$ (64,795,382)	$ (4,921,766)
Net loss per common share:
Basic	$ (4.49)	$ (0.25)	$ (6.72)	$ (0.74)
Diluted	$ (4.49)	$ (0.25)	$ (6.72)	$ (0.74)
Weighted average shares used in computing net loss per common share:
Basic	12,666,414	7,701,332	9,640,249	6,651,255
Diluted	12,666,414	7,701,332	9,640,249	6,651,255

Statements Of Cash Flows - USD ($)	9 Months Ended
Statements Of Cash Flows - USD ($)	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities
Net loss	$ (64,795,382)	$ (4,921,766)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	705,717	989,501
Amortization	224,875	224,875
Amortization of deferred finance costs and debt discounts	7,702,681	1,978,264
Share-based compensation	670,873	1,979,159
Loss on asset disposal	16,886	4,122
Adjustment of warrants and convertible debt features	46,758,917	(9,679,848)
Interest due from issuance of stock	551,296
Changes in operating assets and liabilities:
Accounts receivable	3,474,806	594,397
Other receivables	52,522	17,910
Inventories	360,209	(693,139)
Prepaid expenses and other current assets	527,500	(279,595)
Other assets	(828)	1,648
Accounts payable	(362,872)	(1,033,514)
Accrued liabilities	1,477,987	(560,126)
Deferred revenue	(2,287,620)	(660,196)
Other liabilities		(3,093)
Net cash used in operating activities	(4,922,433)	(12,041,401)
Cash flows from investing activities
Purchase of equipment		(130,103)
Net cash used in investing activities		(130,103)
Cash flows from financing activities
Payments of term note	(4,000,000)	(3,000,000)
Proceeds from revolving line of credit	37,237,131	42,246,305
Payments of revolving line of credit	(41,490,148)	(49,363,204)
Proceeds from subordinated convertible debt, net of issuance costs		7,738,351
Proceeds from Healthcare Royalty Partners debt	2,500,000	2,500,000
Payments of Healthcare Royalty Partners debt	(263,192)	(1,114,095)
Proceeds from issuance of stock and warrants, net of issuance costs	11,547,529	9,122,431
Net cash provided by financing activities	5,531,320	8,129,788
Net decrease in cash and cash equivalents	608,887	(4,041,716)
Cash and cash equivalents at beginning of period	7,777,718	13,954,919
Cash and cash equivalents at end of period	$ 8,386,605	$ 9,913,203

Summary Of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the nine month period ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013 or for future operating periods.

These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission (SEC) on April 1, 2013.

As described in Note 10, on July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. All information set forth in the financial statements and related notes gives effect to such reverse stock split.

Financial Instruments

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants and debt conversion features. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.

The following methods and assumptions were used by the Company in estimating its fair value disclosures for other financial instruments as of September 30, 2013 and December 31, 2012.

Cash equivalents, accounts receivable, and accounts payable have carrying values which approximate fair value due to the short maturity or the financial nature of these instruments.

Long and short-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value. See Note 9 for disclosure of the fair value of debt.

Revenue and Costs of Revenue

For arrangements with multiple deliverables, the Company allocates the total revenue to each deliverable based on the provisions of general accounting principles for revenue recognition and multiple-deliverable revenue arrangements and recognizes revenue for each separate element as the criteria for revenue recognition are met. Each element is assigned an estimated selling price using vendor-specific objective evidence, third party evidence, or management’s estimate.

Under our revenue recognition policy, a portion of revenue for the Niobe, Odyssey Vision, Odyssey Cinema, and Vdrive systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue for Niobe, Odyssey Vision Standard HD, Odyssey Vision Quad, Odyssey Cinema, and Vdrive systems is recognized upon delivery due to the fact that third parties became qualified to perform installations. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. However, the Company may deliver systems to a non-hospital site at the customer’s request as outlined in the terms and conditions of the sales agreement, in which case the Company evaluates whether the substance of the transaction meets the delivery and performance requirements for revenue recognition under “bill and hold” guidance. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue.

Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.

Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.

Share-Based Compensation

The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.

The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.

Net Loss per Common Share (“EPS”)

Basic and diluted net loss per common share (“EPS”) is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.

The following table sets forth the computation of basic and diluted EPS:


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Numerator:
Numerator for basic EPS	$	(56,868,442)	$	(1,915,281)	$	(64,795,382)	$	(4,921,766)
Effect of dilutive securities:
Subordinated convertible debentures		—		—		—		—
Numerator for diluted EPS	$	(56,868,442)	$	(1,915,281)	$	(64,795,382)	$	(4,921,766)
Denominator:
Denominator for basic EPS—weighted average shares		12,666,414		7,701,332		9,640,249		6,651,255
Effect of dilutive securities:
Subordinated convertible debentures		—		—		—		—
Denominator for diluted EPS		12,666,414		7,701,332		9,640,249		6,651,255
Basic EPS	$	(4.49)	$	(0.25)	$	(6.72)	$	(0.74)
Diluted EPS	$	(4.49)	$	(0.25)	$	(6.72)	$	(0.74)

In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for the three and nine months ended September 30, 2013 and the three and nine months ended September 30, 2012. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.

As of September 30, 2013, the Company had 238,989 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $46.83 per share and 3,021,302 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $14.30 per share. The Company had a weighted average of 25,657 and 36,135 unearned restricted shares outstanding for the three and nine months period ended September 30, 2013.

Recently Issued Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU” or “Update”) 2013-02, “Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (“AOCI”). The update requires that the Company present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of AOCI based on its source and the income statement line items affected by the reclassification. The guidance is effective for interim and annual reporting periods beginning on or after December 15, 2012. As the Company has no items of other comprehensive income, the Company is not required to report accumulated other comprehensive income.

In December 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-11, “Disclosures about Offsetting Assets and Liabilities.” The Update enhances the disclosure of offsetting assets and liabilities by requiring companies to disclose both the gross and net information about instruments and transactions eligible for offset as well as those subject to an agreement similar to master netting arrangements. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2013. The adoption of this pronouncement did not have an impact on the financial statements.

In June 2011, the FASB issued new accounting guidance related to the presentation of comprehensive income that increases comparability between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This guidance eliminates the current option to report other comprehensive income (OCI) and its components in the statement of changes in stockholders’ equity and requires the presentation of a separate statement of comprehensive income. This guidance was effective for the Company’s interim and annual periods beginning January 1, 2012. As the Company has no items of other comprehensive income, the Company is not required to report comprehensive income or other comprehensive income.

Long-Term Debt And Credit Facilities

9 Months Ended

Sep. 30, 2013

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:


	September 30, 2013		December 31, 2012
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due March 2014	$ 3,000,000	$ 3,018,067	$ 7,253,017	$ 7,277,084
Term note, due December 2013	—	—	4,000,000	4,000,000
Healthcare Royalty Partners debt	18,484,883	18,484,883	16,248,075	16,248,075
Subordinated convertible debentures	—	—	1,588,134	1,588,134
Total debt	21,484,883	21,502,950	29,089,226	29,113,293
Less current maturities	(3,242,800)	(3,260,867)	(12,264,490)	(12,288,557)
Total long term debt	$ 18,242,083	$ 18,242,083	$ 16,824,736	$ 16,824,736

In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of September 30, 2013 and December 31, 2012. Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3). The carrying amounts of the Subordinated Convertible Debentures are net of the respective unamortized debt discount as of December 31, 2012.

Revolving line of credit

In September 2011, the Company amended its agreement with its primary lender. The amendment reduced the availability amount of all credit extensions, other than the term loan, from $30 million to $20 million, and modified the interest rate applicable to the term loan from the lender’s prime rate plus 3.5% to the lender’s prime rate plus 5.5%.

On November 30, 2011, the Company entered into a Second Amended and Restated Loan and Security Agreement with its primary lender (“Amended Loan Agreement”). Under the Amended Loan Agreement, the Company agreed to revised tangible net worth and liquidity ratio covenants. Further, certain intellectual property assets of the Company were added to the collateral which secures repayment of the loan. Finally, the Amended Loan Agreement permits the Company to repay Healthcare Royalty Partners II, L.P. (“Healthcare Royalty Partners”), formerly “Cowen Healthcare Royalty Partners II, L.P.”, with the royalties due to the Company under the Biosense Agreement (the "Biosense Agreement"), as described below.

On March 30, 2012, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2012 to April 30, 2012 and reduced the Company’s borrowing availability by $3,333,333. The Company also received from stockholders, who at the time were affiliates of two members of our board of directors (the “Lenders”) and were considered to be related parties, an extension of their commitment to provide $10 million in loan guarantees until April 30, 2012. As a result of this extension, the Company issued the Lenders warrants to purchase 75,735 shares of common stock at $6.60 per share.

On May 1, 2012, the Company and its primary lender entered into an agreement in which the lender extended the maturity of the revolving line of credit from April 30, 2012 to May 15, 2012. The Company and the Lenders also agreed to amend their agreement to extend the $10 million loan guarantee through May 15, 2012. The Company granted warrants to purchase an aggregate of 60,976 shares of common stock at $4.10 per share in exchange for the extension of the guarantee.

On May 10, 2012, upon closing of financing transactions for gross proceeds of $18.5 million, the Company entered into the Third Loan Modification Agreement with its primary lender. The amendment extended the revolving credit facility maturity to March 31, 2013 and revised the financial covenants. Additionally, the revolving line of credit was decreased from $20 million to $13 million. The reduction was as a result of the pay down of $7 million of the guarantees provided by the Lenders. In addition the Company and the Lenders agreed to decrease the $10 million guarantee to $3 million and to further extend the loan guarantee through March 31, 2013. The Company granted warrants to purchase an aggregate of 234,305 shares of common stock at $3.361 per share in exchange for the extension of the guarantee.

On March 29, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2013 to June 30, 2013. The Company and the Lenders also agreed to extend until June 30, 2013 the $3 million guarantee. As a result of this extension, the Company issued the Lenders warrants to purchase 113,636 shares of common stock at $1.98 per share.

On June 28, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from June 30, 2013 to July 31, 2013, and decreased the amount of available advances from $13 million to $6 million. In addition, the Bank waived the testing of the tangible net worth and liquidity ratio financial covenants under the Amended Loan Agreement for the period ended June 30, 2013. The Company and the Lenders also agreed to extend until July 31, 2013 the $3 million guarantee. As a result of this extension, the Company issued the Lenders warrants to purchase 48,387 shares of common stock at $1.55 per share.

On July 31, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from July 31, 2013 to August 31, 2013. In addition, the Bank waived the testing of the liquidity ratio financial covenant under the Amended Loan Agreement for the period ended July 31, 2013. The Company and the Lenders also agreed to extend until August 31, 2013 the $3 million guarantee. As a result of this extension, the Company issued the Lenders warrants to purchase 14,313 shares of common stock at $5.24 per share.

On August 30, 2013, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from August 31, 2013 to March 31, 2014. In addition, the Company and the Bank agreed to a reduction in the revolving credit line from $6.0 million to $3.0 million, the elimination of the $3.0 million sublimit guaranteed by the Lenders, and release of the guarantees by the Lenders in favor of the Bank. The amendment eliminated the prepayment premium for the prepayment of the term loan and modified the financial covenants to (a) eliminate the minimum tangible net worth covenant, (b) substitute in lieu thereof an EBITDA test, requiring the Company to maintain a minimum EBITDA of no less than (no worse than) (i) negative $4.0 million for the trailing three-month period ending September 30, 2013 and (ii) negative $3.0 million for the trailing three-month period ending December 31, 2013, in each case tested quarterly on a trailing three month basis, and (c) revise the liquidity ratio covenant to require the Company to maintain a liquidity ratio of greater than 2:1, excluding certain short term advances from the calculation.

As of September 30, 2013, the Company had $3.0 million outstanding under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of September 30, 2013, the Company had a borrowing capacity of $3.0 million based on the Company’s collateralized assets, including amounts already drawn. As such, the Company had no remaining ability to borrow under the revolving line of credit at September 30, 2013.

The revolving line of credit and the Company’s term notes (collectively, the “Credit Agreements”) are secured by substantially all of the Company’s assets. The Company is also required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

Term note

Under the 2010 amendment to the loan agreement, the Company entered into a $10 million term loan maturing on December 31, 2013, with $2 million of principal due in 2011 and $4 million of principal due in each of 2012 and 2013. Interest on the term loan accrued at the rate of prime plus 3.5%. Under the September 2011 amendment of the loan agreement, the interest rate on the term loan was increased to prime plus 5.5%. Under this agreement, the Company provided its primary lender with warrants to purchase 11,111 shares of common stock. The warrants are exercisable at $36.00 per share, beginning on December 17, 2010 and expiring on December 17, 2015. The fair value of these warrants of $228,332, calculated using the Black-Scholes method, was deferred and amortized to interest expense ratably over the life of the term loan. The term note was paid in full in September 2013.

Healthcare Royalty Partners Debt

In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners. Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender under the Amended Loan Agreement described above.

Subordinated Convertible Debentures

In May 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures (the “Debentures”), which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction. The purchasers of the Debentures also received six-year warrants to purchase an aggregate of approximately 2.5 million shares of the Company’s common stock at an exercise price of $3.361 per share (“Convert Warrants”). The Debentures bear interest at 8% per year and mature on May 7, 2014. In addition, the Company has the ability to issue shares of its common stock in lieu of cash interest payments under certain circumstances, and following the registration of the shares for resale, the Company issued shares in lieu of cash interest payments.

The Company recorded the Debentures on the balance sheet net of the debt discount. The debt discount of $7.6 million is due to warrants issued in conjunction with the Debentures and the debt conversion features. Upon issuance of the Debentures, the fair value of the warrants and derivative liability were $4.1 million and $3.5 million, respectively. The debt discount was amortized over the life of the loan using the effective interest method and the warrants and derivative liability were recorded at fair value on each reporting period. Refer to Note 11 for additional discussion of the fair value of the warrants and conversion features.

On August 7, 2013, holders of Convert Warrants exercised all of their Convert Warrants for an aggregate of approximately 2.5 million shares of our common stock, resulting in cash proceeds of approximately $8.5 million. In addition, holders of all of the Debentures exchanged the balance of their unconverted Debentures for an aggregate of approximately 2.7 million shares of the Company’s common stock and additional warrants (the “Exchange Warrants”) to purchase approximately 2.5 million shares, having an exercise price of $3.361 per share. On August 8, 2013, certain former holders of the Debentures exercised Exchange Warrants to purchase an aggregate of 1,372,358 shares of common stock in cashless net exercises as provided for in the Exchange Warrants, which resulted in the issuance to such funds of an aggregate of 841,575 shares of common stock. As a result, there were no net proceeds to the Company. The Company is relying on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, based on representations to the Company made by the warrant holders.

The costs associated with the adjustment of warrants and convertible debt features in connection with the third quarter capital transactions are included in other expense for the three and nine months ended September 30, 2013. The costs associated with the write-off of the unamortized debt discount are included in interest expense for the three and nine months ended September 30, 2013.

Stockholders' Equity

9 Months Ended

Sep. 30, 2013

Stockholders' Equity [Abstract]

Stockholders' Equity

10. Stockholders’ Equity

Listing Transfer to NASDAQ Capital Market

On August 15, 2013, the NASDAQ Listing Qualifications Panel (the “Panel”) granted approval of the Company’s request to transfer its listing to The NASDAQ Capital Market® from The NASDAQ Global Market®. The Company’s securities began trading on the NASDAQ Capital Market effective August 19, 2013.

Reverse Stock Split

On July 10, 2012, the Company filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to implement a one-for-ten reverse split of our common stock (the “Reverse Stock Split”). The ratio for the Reverse Stock Split was determined by our Board of Directors pursuant to the approval of the stockholders at the Company’s special meeting of stockholders held on July 10, 2012, authorizing the Board to effect a reverse stock split within a range of one-for-four to one-for-ten shares of the Company’s common stock. The Reverse Stock Split was effective as of July 10, 2012, and the Company’s common stock began trading on the NASDAQ Global Market on a post-split basis on July 11, 2012.

As a result of the Reverse Stock Split, each ten shares of the Company’s issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Reverse Stock Split affected all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, stock appreciation rights, restricted stock, restricted stock units, warrants and convertible debentures outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split reduced the number of shares of the Company’s common stock outstanding from approximately 78 million to 7.8 million at the time of the Reverse Stock Split. In addition, the Amendment increased the number of authorized shares of the Company’s common stock from 100 million to 300 million. The Reverse Stock Split did not alter the par value of common stock, which remained $0.001 per share, or modify any voting rights or other terms of the Company’s common stock. Unless otherwise indicated, all information set forth herein gives effect to such Reverse Stock Split.

Private Offerings of Common Stock

In May 2012, the Company entered into a Stock and Warrant Purchase Agreement with certain institutional investors whereby it agreed to sell an aggregate of approximately 2.17 million shares of the Company's common stock (the “PIPE Common Stock”) at a price of $3.361 per share, together with six-year warrants at a price of $1.25 per share to purchase an aggregate of approximately 2.17 million shares of common stock having an exercise price of $3.361 per share (the “PIPE Warrants”). Each purchaser received a PIPE Warrant to purchase one share of common stock for every share of PIPE Common Stock purchased.

Net proceeds from the sale of the securities were approximately $9.1 million, after placement agent fees and other offering expenses. The Company used the funds to repay $7 million of the revolving credit facility guaranteed by the Lenders and plans to use the balance for working capital and general corporate purposes.

On August 7, 2013, venture funds affiliated with Sanderling Ventures received an aggregate of 183,478 shares of common stock based upon the cashless exercise of warrants to purchase an aggregate of 262,450 shares of common stock. These warrants were comprised of 75,758 warrants with an exercise price of $1.98 per share, 156,204 warrants with an exercise price of $3.361 per share and 30,488 warrants with an exercise price of $4.10 per share. The warrants were issued by the Company in private placements in 2012 and 2013 in connection with the extension of previously disclosed guarantees.

On August 13, 2013, venture funds affiliated with Sanderling Ventures exercised PIPE Warrants to purchase an aggregate of 650,619 shares of common stock in a cashless net exercise as provided for in the PIPE Warrants, which resulted in the issuance to such funds of an aggregate of 308,194 shares of common stock. As a result, there were no net proceeds to the Company.

On August 16, 2013, certain affiliates of Franklin Templeton exercised PIPE Warrants to purchase an aggregate of 650,618 shares of common stock for cash. The Company received an aggregate of $2,186,727 gross proceeds from the sale.

On August 16, 2013, Alafi Capital Company exercised PIPE Warrants to purchase an aggregate of 261,241 shares of common stock for cash. The Company received an aggregate of $878,031 gross proceeds from the sale.

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012. At September 30, 2013, the Board of Directors had 1,033,242 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans.

At September 30, 2013, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.7 million, net of estimated forfeitures of approximately $1.6 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures and anticipated vesting periods.

A summary of the option and stock appreciation rights activity for the nine month period ended September 30, 2013 is as follows:


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2012	373,899	$1.63 - $116.40	$ 43.90
Granted	-	$0.00 - $0.00	-
Exercised	(145)	$6.80	$ 6.80
Forfeited	(134,765)	$1.69 - $68.60	$ 38.75
Outstanding, September 30, 2013	238,989	$1.63 - $116.40	$ 46.83

A summary of the restricted share grant activity for the nine month period ended September 30, 2013 is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2012	68,543	$ 20.62
Granted	-	-
Vested	(33)	$ 33.80
Forfeited	(37,295)	$ 18.29
Outstanding, September 30, 2013	31,215	$ 23.39

A summary of the restricted shares outstanding as of September 30, 2013 is as follows:


	Number of Shares

Time based restricted shares	7,675
Performance based restricted shares	23,540
Outstanding, September 30, 2013	31,215

A summary of the restricted stock unit activity for the nine month period ended September 30, 2013 is as follows:


	Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2012	529,312	$ 2.64
Granted	447,000	$ 2.20
Vested	(201,306)	$ 3.92
Forfeited	(176,717)	$ 2.09
Outstanding, September 30, 2013	598,289	$ 2.04

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2013

Fair Value Measurements [Abstract]

Fair Value Measurements

11. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at September 30, 2013:
Cash equivalents	$	4,550,340	4,550,340	—	—
Total assets at fair value	$	4,550,340	4,550,340	—	—
Liabilities at September 30, 2013:
Warrants issued December 29, 2008	$	256,650	—	—	256,650
Warrants issued May 10, 2012		1,591,409	—	—	1,591,409
Warrants issued August 2013		3,107,529			3,107,529
Total liabilities at fair value:	$	4,955,588	—	—	4,955,588
Assets at December 31, 2012:
Cash equivalents	$	256,702	256,702	—	—
Derivative asset		1,736	—	—	1,736
Total assets at fair value	$	258,438	256,702	—	1,736
Liabilities at December 31, 2012:
Warrants issued December 29, 2008	$	71,581	—	—	71,581
Warrants issued May 10, 2012		2,347,902	—	—	2,347,902
Derivative liability		548,865	—	—	548,865
Total liabilities at fair value:	$	2,968,348	—	—	2,968,348

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $4,550,340 and $256,702 at September 30, 2013 and December 31, 2012, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the nine month periods ended September 30, 2013 and September 30, 2012. There were no transfers in or out of Level 1 during the period ended September 30, 2013.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with its December 29, 2008 registered direct offering, the Company issued warrants to purchase 179,241 shares of the Company’s common stock that contained a provision that required a reduction of the exercise price if certain equity events occurred. Under the provisions of general accounting principles for derivatives and hedging activities and determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, such a reset provision does not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations. General accounting principles for determining whether an instrument (or embedded feature) is indexed to an entity’s own stock became effective for the Company as of January 1, 2009. Accordingly, the fair value of the warrants as of that date was reclassified from stockholders’ equity into current liabilities.

In accordance with general accounting principles for fair value measurement, the Company’s warrants in the amount of $256,650 were measured at fair value on a recurring basis as of September 30, 2013 and were valued using Level 3 valuation inputs. A Black-Scholes model was used to value the Company’s warrants at September 30, 2013 using the following assumptions: 1) dividend yield of 0%; 2) volatility of 232.47%; 3) risk-free interest rate of 0.63%; and 4) expected life of 0.74 of a year.

In the Company’s May 2012 financing transaction, the Company issued subordinated convertible debentures and warrants. The optional conversion feature of the subordinated convertible debentures is classified as a derivative liability within “Warrants and debt conversion features” on the Company’s balance sheet. In August 2013, holders of all of the Debentures exchanged the balance of their unconverted Debentures for an aggregate of approximately 2.7 million shares of the Company’s common stock and additional warrants (the “Exchange Warrants”) to purchase approximately 2.5 million shares, having an exercise price of $3.361 per share. The warrants issued in conjunction with the May 2012 Debentures and PIPE and the August 2013 Exchange are also considered a liability. Due to the provisions included in the warrant agreements, the warrants do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The warrants and derivative liability are periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

Per the terms of the Debentures agreement, the Company had the ability to require each holder to convert up to 50% of the Debentures if the common stock closed above $15.00, or 100% of the Debentures if the common stock closed above $20.00 (in each case, as adjusted for stock splits, recapitalizations and similar events) during a 20 consecutive trading day period and the resale registration statement had been declared effective by the SEC and was available for the issuance of the common stock upon conversion of the Debentures. In the event of any forced conversion by the Company, the minimum amount that the Company could force the holders to convert was $2.5 million of Debentures in the aggregate. This mandatory redemption clause was classified as a derivative asset within “Prepaid and other current assets” on the Company’s balance sheet. The derivative asset was periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

Based on the discussion of the Debentures in Note 9, the Debentures along with their derivative liability and asset, and related warrants were extinguished prior to September 30, 2013. In accordance with general accounting principles for fair value measurement, the Company’s remaining PIPE and Exchange warrants were measured at fair value on a recurring basis as of September 30, 2013 and were valued using Level 3 valuation inputs. A Monte-Carlo simulation was used to value the derivative asset, liabilities and warrants upon issuance on May 10, 2012 using the following assumptions: 1) volatility of 80%; 2) risk-free interest rate of 1.035%; and 3) a closing stock price of $3.413.

The initial valuation of Exchange warrants were valued as of August 7, 2013 using the following assumptions: 1) volatility of 111%; 2) risk-free interest rate of 1.46%; and 3) a closing stock price of $8.69.

The remaining Exchange warrants were revalued as of September 30, 2013 using the following assumptions: 1) volatility of 115%; 2) risk-free interest rate of 1.43%; and 3) a closing stock price of $3.33.

The remaining PIPE warrants were revalued as of September 30, 2013 using the following assumptions: 1) volatility of 115%; 2) risk-free interest rate of 1.24%; and 3) a closing stock price of $3.33.

The significant unobservable input used in the fair value measurement of the Company’s warrants, derivative liability, and derivative asset is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) asset and liability fair value measurements.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial asset and liabilities for the nine month period ended September 30, 2013:


	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 2012	Warrants issued August 2013	Derivative Liability	Total Liabilities
Balance at beginning of period	$ 1,736	$ 1,736	$ 71,581	$ 2,347,902	-	$ 548,865	$ 2,968,348
Issues	-	-	-		19,358,108		19,358,108
Settlements	-	-	-	(18,780,167)	(10,535,592)	(12,828,650)	(42,144,409)
Revaluation	(1,736)	(1,736)	185,069	18,023,674	(5,714,987)	12,279,785	24,773,541
Balance at end of period	$ -	$ -	$ 256,650	$ 1,591,409	$ 3,107,529	$ -	$ 4,955,588

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary Of Significant Accounting Policies (Policy)

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Basis Of Presentation

Basis of Presentation

Financial Instruments

The following methods and assumptions were used by the Company in estimating its fair value disclosures for other financial instruments as of September 30, 2013 and December 31, 2012.

Cash equivalents, accounts receivable, and accounts payable have carrying values which approximate fair value due to the short maturity or the financial nature of these instruments.

Long and short-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value. See Note 9 for disclosure of the fair value of debt.

Revenue And Costs Of Revenue

Revenue and Costs of Revenue

Share-Based Compensation

Net Loss Per Common Share

Net Loss per Common Share (“EPS”)

Basic and diluted net loss per common share (“EPS”) is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.

The following table sets forth the computation of basic and diluted EPS:


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Numerator:
Numerator for basic EPS	$	(56,868,442)	$	(1,915,281)	$	(64,795,382)	$	(4,921,766)
Effect of dilutive securities:
Subordinated convertible debentures		—		—		—		—
Numerator for diluted EPS	$	(56,868,442)	$	(1,915,281)	$	(64,795,382)	$	(4,921,766)
Denominator:
Denominator for basic EPS—weighted average shares		12,666,414		7,701,332		9,640,249		6,651,255
Effect of dilutive securities:
Subordinated convertible debentures		—		—		—		—
Denominator for diluted EPS		12,666,414		7,701,332		9,640,249		6,651,255
Basic EPS	$	(4.49)	$	(0.25)	$	(6.72)	$	(0.74)
Diluted EPS	$	(4.49)	$	(0.25)	$	(6.72)	$	(0.74)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Computation Of Basic And Diluted EPS


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Numerator:
Numerator for basic EPS	$	(56,868,442)	$	(1,915,281)	$	(64,795,382)	$	(4,921,766)
Effect of dilutive securities:
Subordinated convertible debentures		—		—		—		—
Numerator for diluted EPS	$	(56,868,442)	$	(1,915,281)	$	(64,795,382)	$	(4,921,766)
Denominator:
Denominator for basic EPS—weighted average shares		12,666,414		7,701,332		9,640,249		6,651,255
Effect of dilutive securities:
Subordinated convertible debentures		—		—		—		—
Denominator for diluted EPS		12,666,414		7,701,332		9,640,249		6,651,255
Basic EPS	$	(4.49)	$	(0.25)	$	(6.72)	$	(0.74)
Diluted EPS	$	(4.49)	$	(0.25)	$	(6.72)	$	(0.74)

Stockholder's Equity (Tables)

9 Months Ended

Sep. 30, 2013

Summary Of The Option And Stock Appreciation Rights Activity


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2012	373,899	$1.63 - $116.40	$ 43.90
Granted	-	$0.00 - $0.00	-
Exercised	(145)	$6.80	$ 6.80
Forfeited	(134,765)	$1.69 - $68.60	$ 38.75
Outstanding, September 30, 2013	238,989	$1.63 - $116.40	$ 46.83

Restricted Stock [Member]

Summary Of The Restricted Share Grant Activity


	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2012	68,543	$ 20.62
Granted	-	-
Vested	(33)	$ 33.80
Forfeited	(37,295)	$ 18.29
Outstanding, September 30, 2013	31,215	$ 23.39

Summary Of The Restricted Shares Outstanding


	Number of Shares

Time based restricted shares	7,675
Performance based restricted shares	23,540
Outstanding, September 30, 2013	31,215

Summary Of The Restricted Stock Unit Activity


	Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2012	529,312	$ 2.64
Granted	447,000	$ 2.20
Vested	(201,306)	$ 3.92
Forfeited	(176,717)	$ 2.09
Outstanding, September 30, 2013	598,289	$ 2.04

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2013

Fair Value Measurements [Abstract]

Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at September 30, 2013:
Cash equivalents	$	4,550,340	4,550,340	—	—
Total assets at fair value	$	4,550,340	4,550,340	—	—
Liabilities at September 30, 2013:
Warrants issued December 29, 2008	$	256,650	—	—	256,650
Warrants issued May 10, 2012		1,591,409	—	—	1,591,409
Warrants issued August 2013		3,107,529			3,107,529
Total liabilities at fair value:	$	4,955,588	—	—	4,955,588
Assets at December 31, 2012:
Cash equivalents	$	256,702	256,702	—	—
Derivative asset		1,736	—	—	1,736
Total assets at fair value	$	258,438	256,702	—	1,736
Liabilities at December 31, 2012:
Warrants issued December 29, 2008	$	71,581	—	—	71,581
Warrants issued May 10, 2012		2,347,902	—	—	2,347,902
Derivative liability		548,865	—	—	548,865
Total liabilities at fair value:	$	2,968,348	—	—	2,968,348

Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities


	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 2012	Warrants issued August 2013	Derivative Liability	Total Liabilities
Balance at beginning of period	$ 1,736	$ 1,736	$ 71,581	$ 2,347,902	-	$ 548,865	$ 2,968,348
Issues	-	-	-		19,358,108		19,358,108
Settlements	-	-	-	(18,780,167)	(10,535,592)	(12,828,650)	(42,144,409)
Revaluation	(1,736)	(1,736)	185,069	18,023,674	(5,714,987)	12,279,785	24,773,541
Balance at end of period	$ -	$ -	$ 256,650	$ 1,591,409	$ 3,107,529	$ -	$ 4,955,588

Summary Of Significant Accounting Policies (Narrative) (Details)		3 Months Ended	9 Months Ended
	Jul. 10, 2012	Sep. 30, 2013 $ / shares shares	Sep. 30, 2013 $ / shares shares	Dec. 31, 2012 $ / shares shares	Dec. 29, 2008 shares
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split	0.1
Deferred revenue, amortization period			1 year
Share based compensation, requisite service period			4 years
Stock options and stock appreciation rights		238,989	238,989	373,899
Warrants		3,021,302	3,021,302
Weighted average exercise price \| $ / shares		$ 46.83	$ 46.83	$ 43.90
Weighted average exercise price of warrants or rights \| $ / shares		$ 14.30	$ 14.30
Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Weighted average unearned restricted shares outstanding		25,657	36,135
Fair Value, Inputs, Level 3 [Member]
Summary Of Significant Accounting Policies [Line Items]
Warrants					179,241

Summary of Significant Accounting Policies (Computation of Basic and Diluted EPS) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Summary Of Significant Accounting Policies [Abstract]
Numerator for basic EPS	$ (56,868,442)	$ (1,915,281)	$ (64,795,382)	$ (4,921,766)
Subordinated convertible debentures
Numerator for diluted EPS	$ (56,868,442)	$ (1,915,281)	$ (64,795,382)	$ (4,921,766)
Denominator for basic EPS - weighted average shares	12,666,414	7,701,332	9,640,249	6,651,255
Subordinated convertible debentures
Denominator for diluted EPS	12,666,414	7,701,332	9,640,249	6,651,255
Basic EPS	$ (4.49)	$ (0.25)	$ (6.72)	$ (0.74)
Diluted EPS	$ (4.49)	$ (0.25)	$ (6.72)	$ (0.74)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details)	9 Months Ended
	Sep. 30, 2013 USD ($) ft²	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,715,907	$ 2,123,167
Accrued rent	1,494,539	1,095,641
Accrued warranties	546,079	653,473	$ 691,832
Accrued interest	496,197	469,049
Accrued license and maintenance fees	340,696	323,901
Other	1,246,379	696,579
Total accrued liabilities	$ 6,839,797	$ 5,361,810
Square feet of office leased space \| ft²	65,000
Square feet of demonstration and assembly leased space \| ft²	12,000
Square feet of terminated unimproved space leased space \| ft²	13,000
Remaining contractual lease obligation	$ 9,380,545

Long-Term Debt And Credit Facilities (Narrative) (Details) $ / shares in Units, item in Millions				1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 30, 2013 USD ($)	Aug. 07, 2013 USD ($) $ / item shares	May 10, 2012 USD ($) $ / item shares	Jan. 31, 2013 USD ($)	May 31, 2012 USD ($) item $ / shares $ / item shares	Mar. 30, 2012 USD ($) $ / item shares	Nov. 30, 2011 USD ($)	Sep. 30, 2011 USD ($)	Dec. 31, 2010 USD ($) $ / item shares	Dec. 31, 2013 USD ($)	Sep. 30, 2013 USD ($) shares	Sep. 30, 2013 USD ($) shares	Sep. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)	Aug. 31, 2013	Aug. 08, 2013 shares	Jul. 31, 2013 USD ($) $ / item shares	Jun. 28, 2013 USD ($) $ / item shares	Mar. 29, 2013 USD ($) $ / item shares	May 01, 2012 USD ($) $ / item shares
Debt Instrument [Line Items]
Warrants \| shares											3,021,302	3,021,302
Paydown of the guarantees														$ 7,000,000
Proceeds from revolving line of credit												$ 37,237,131	$ 42,246,305
Amount borrowed												2,500,000	2,500,000
Convert Warrants [Member]
Debt Instrument [Line Items]
Aggregate number of shares issued upon conversion \| shares		2,500,000
Proceeds from the exercise of stock warrants		$ 8,500,000
Exchange Warrants [Member]
Debt Instrument [Line Items]
Warrants \| shares		2,500,000
Number of shares issued upon conversion of warrants \| shares																1,372,358
Aggregate number of shares issued upon conversion \| shares		2,700,000														841,575
Proceeds from the exercise of stock warrants												0
Exercise price of warrants \| $ / item		3.361
Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Current borrowing capacity											$ 3,000,000	3,000,000
Line of credit facility, amount outstanding											3,000,000	$ 3,000,000
Term Note [Member]
Debt Instrument [Line Items]
Debt maturity date												Dec. 31, 2013
Warrants \| shares									11,111
Exercise price of warrants \| $ / item									36.00
Fair value of warrants issued									$ 228,332
Term loan agreement, face value									10,000,000
Healthcare Royalty Partners debt [Member]
Debt Instrument [Line Items]
Debt maturity date												Dec. 31, 2018
Amount borrowed							$ 15,000,000
Additional amount which may be borrowed							$ 5,000,000
Percentage of royalties entitled to							100.00%
Annual interest rate							16.00%
Additional amount borrowed				$ 2,500,000									$ 2,500,000
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Warrants \| shares					2,500,000
Exercise price of warrants \| $ / item					3.361
Annual interest rate					8.00%
Proceeds from Convertible Debt					$ 8,500,000
Conversion price per share \| $ / shares					$ 3.361
Number of convertible shares \| item					2.5
Debt discount					$ 7,600,000
Fair value of warrants					4,100,000
Fair value of derivative liability					$ 3,500,000
Unconverted Debentures [Member]
Debt Instrument [Line Items]
Aggregate number of shares issued upon conversion \| shares		2,700,000
March 30, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 10,000,000
Revolving credit agreement, maturity date												Apr. 30, 2012
Decrease in maximum borrowing capacity						$ 3,333,333
Warrants \| shares						75,735
Exercise price of warrants \| $ / item						6.60
May 1, 2012 Agreement [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Revolving credit agreement, maturity date												May 15, 2012
Warrants \| shares																				60,976
Exercise price of warrants \| $ / item																				4.10
May 10, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Revolving credit agreement, maturity date												Mar. 31, 2013
Aggregate number of shares issued upon conversion \| shares			234,305
Exercise price of warrants \| $ / item			3.361
Current borrowing capacity			$ 13,000,000
Net proceeds from issuance of long-term debt			18,500,000
March 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Revolving credit agreement, maturity date												Jun. 30, 2013
Warrants \| shares																			113,636
Exercise price of warrants \| $ / item																			1.98
June 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity																		$ 13,000,000
Revolving credit agreement, maturity date												Jul. 31, 2013
Warrants \| shares																		48,387
Exercise price of warrants \| $ / item																		1.55
Current borrowing capacity																		$ 6,000,000
Guaratees Provided By Lenders [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			3,000,000														$ 3,000,000	$ 3,000,000	$ 3,000,000	$ 10,000,000
Paydown of the guarantees			$ 7,000,000
July 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Revolving credit agreement, maturity date												Aug. 31, 2013
Warrants \| shares																	14,313
Exercise price of warrants \| $ / item																	5.24
August 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 3,000,000
Revolving credit agreement, maturity date												Mar. 31, 2014
Decrease in maximum borrowing capacity	$ 3,000,000
Liquidity ratio															2
September 2011 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 20,000,000
2010 Amendment To Loan Agreement [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity									30,000,000
Principal Due 2013 [Member]
Debt Instrument [Line Items]
Term loan principal amount due											4,000,000	$ 4,000,000
Principal Due 2012 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due											4,000,000	$ 4,000,000
Principal Due 2011 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due									$ 2,000,000
Prime Rate Plus [Member] \| September 2011 Amendment [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate								5.50%
Prime Rate Plus [Member] \| 2010 Amendment To Loan Agreement [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Interest rate added to prime rate									3.50%
Maximum [Member] \| August 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Earnings before interest and depreciation and amortization revolving credit convenant											$ (4,000,000)
Maximum [Member] \| Scenario, Forecast [Member] \| August 2013 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Earnings before interest and depreciation and amortization revolving credit convenant										$ (3,000,000)

Long-Term Debt And Credit Facilities (Schedule Of Long-Term Debt Outstanding) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Total debt, Carrying Amount	$ 21,484,883	$ 29,089,226
Total debt, Estimated Fair Value	21,502,950	29,113,293
Less current maturities, Carrying Amount	(3,242,800)	(12,264,490)
Less current maturities, Estimated Fair Value	(3,260,867)	(12,288,557)
Total long term debt, Carrying Amount	18,242,083	16,824,736
Total long term debt, Estimated Fair Value	18,242,083	16,824,736
Revolving Credit Agreement Due March 2014 [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	3,000,000	7,253,017
Total debt, Estimated Fair Value	$ 3,018,067	7,277,084
Revolving credit agreement, maturity date	Mar. 01, 2014
Term Note, Due December 2013 [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount		4,000,000
Total debt, Estimated Fair Value		4,000,000
Term note, maturity date	December 2013
Healthcare Royalty Partners debt [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	$ 18,484,883	16,248,075
Total debt, Estimated Fair Value	$ 18,484,883	16,248,075
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount		1,588,134
Total debt, Estimated Fair Value		$ 1,588,134

Stockholders' Equity (Narrative) (Details)		1 Months Ended		9 Months Ended	12 Months Ended
Stockholders' Equity (Narrative) (Details)	Jul. 10, 2012 shares	Aug. 16, 2013 USD ($) shares	May 31, 2012 $ / shares $ / item shares	Sep. 30, 2013 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Aug. 13, 2013 shares	Aug. 07, 2013 $ / item shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split	0.1
Common stock outstanding				15,925,480	8,018,615
Common stock authorized	100,000,000			300,000,000	300,000,000
Common stock authorized due to Amendment				300,000,000
Common stock par value \| $ / shares				$ 0.001	$ 0.001
Duration period of warrants			6 years
Net proceeds from sale of securities \| $					$ 9,100,000
Paydown of the guarantees \| $					$ 7,000,000
Remaining shares of Company's common stock to provide for current and future grants under its various equity plans				1,033,242
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees \| $				$ 1,700,000
Estimated forfeitures \| $				$ 1,600,000
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees, period of amortization, in years				4 years
Exercise of options/SAR's, shares				145
Pre-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding	78,000,000
Shares sold in private placement			2,170,000
Share price of shares sold in private placement \| $ / item			3.361
Warrants sold in private placement			2,170,000
Share price of warrants sold in private placement \| $ / shares			$ 1.25
Exercise price of warrants \| $ / item			3.361
Post-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding	7,800,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized reverse stock split	0.25
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized reverse stock split	0.1
Warrrant Exercise Price $1.98 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / item							1.98
Cashless exercise of warrants conversion to common stock							75,758
Warrrant Exercise Price $3.361 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / item							3.361
Cashless exercise of warrants conversion to common stock							156,204
Warrrant Exercise Price $4.10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants \| $ / item							4.10
Cashless exercise of warrants conversion to common stock							30,488
Sanderling Ventures PIPE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued upon conversion of warrants						308,194	183,478
Cashless exercise of warrants conversion to common stock						650,619	262,450
Franklin Templeton PIPE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued upon conversion of warrants		650,618
Proceeds from the exercise of stock warrants \| $		$ 2,186,727
Alafi Capital Company PIPE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued upon conversion of warrants		261,241
Proceeds from the exercise of stock warrants \| $		$ 878,031

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Activity) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2012	373,899
Number of Options/SARs, Exercised	(145)
Number of Options/SARs, Forfeited	(134,765)
Number of Options/SARs, Outstanding, September30, 2013	238,989	373,899
Weighted Average Exercise Price per Share, Outstanding, December 31, 2012	$ 43.90
Weighted Average Exercise Price per Share, Exercised	6.80
Weighted Average Exercise Price per Share, Forfeited	38.75
Weighted Average Exercise Price per Share, Outstanding, September 30, 2013	46.83	$ 43.90
$1.63 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit		1.63
Range of Exercise Price, Upper limit		$ 116.40
$0.00 - $0.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	0.00
Range of Exercise Price, Upper limit	0.00
$6.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	6.80
$8.10 - $68.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	1.69
Range of Exercise Price, Upper limit	68.60
$1.63 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	1.63
Range of Exercise Price, Upper limit	$ 116.40

Stockholders' Equity (Summary Of The Restricted Share Grant Activity) (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2013 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2012 \| shares	68,543
Number of Shares, Vested \| shares	(33)
Number of Shares, Forfeited \| shares	(37,295)
Number of Shares, Outstanding, September 30, 2013 \| shares	31,215
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012 \| $ / shares	$ 20.62
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	33.80
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	18.29
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, September 30, 2013 \| $ / shares	$ 23.39

Stockholders' Equity (Summary Of The Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2013 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2012 \| shares	529,312
Number of Shares, Granted \| shares	447,000
Number of Shares, Vested \| shares	(201,306)
Number of Shares, Forfeited \| shares	(176,717)
Number of Shares, Outstanding, September 30, 2013 \| shares	598,289
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2012 \| $ / shares	$ 2.64
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares	2.20
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	3.92
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	2.09
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, September 30, 2013 \| $ / shares	$ 2.04

Fair Value Measurements (Narrative) (Details)			9 Months Ended
Fair Value Measurements (Narrative) (Details)	Aug. 07, 2013 $ / shares $ / item shares	May 10, 2012 USD ($) $ / shares $ / item	Sep. 30, 2013 USD ($) $ / shares shares	Aug. 08, 2013 shares	Dec. 31, 2012 USD ($)	Dec. 29, 2008 shares
Fair Value Measurements [Line Items]
Cash equivalents invested in money market funds \| $			$ 4,550,340		$ 256,702
Issued warrants to purchase shares of common stock \| shares			3,021,302
Mandatory conversion minimum per Debentures agreement \| $		$ 2,500,000
Warrants Issued December 29, 2008 [Member]
Fair Value Measurements [Line Items]
Fair value of warrants issued \| $			$ 256,650		71,581
Common Stock Closes Above $15.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement		50.00%
Share price which determines conversion per Debentures agreement \| $ / item		15.00
Common Stock Closes Above $20.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement		100.00%
Share price which determines conversion per Debentures agreement \| $ / item		20.00
Number of consecutive trading days required at stock price		20 days
Black-Scholes Model Used to Value Warrants [Member]
Fair Value Measurements [Line Items]
Dividend yield			0.00%
Volatility rate			232.47%
Risk-free interest rate			0.63%
Expected life			8 months 27 days
Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate		80.00%
Risk-free interest rate		1.035%
Closing stock price \| $ / shares		$ 3.413
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurements [Line Items]
Cash equivalents invested in money market funds \| $			$ 4,550,340		256,702
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements [Line Items]
Issued warrants to purchase shares of common stock \| shares						179,241
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value Measurements [Line Items]
Fair value of warrants issued \| $			$ 256,650		$ 71,581
Convert Warrants [Member]
Fair Value Measurements [Line Items]
Aggregate number of shares issued upon conversion \| shares	2,500,000
Exchange Warrants [Member]
Fair Value Measurements [Line Items]
Issued warrants to purchase shares of common stock \| shares	2,500,000
Aggregate number of shares issued upon conversion \| shares	2,700,000			841,575
Exercise price of warrants \| $ / item	3.361
Exchange Warrants [Member] \| Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate	111.00%		115.00%
Risk-free interest rate	1.46%		1.43%
Closing stock price \| $ / shares	$ 8.69		$ 3.33
PIPE Warrants [Member] \| Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate			115.00%
Risk-free interest rate			1.24%
Closing stock price \| $ / shares			$ 3.33

Fair Value Measurements (Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level) (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 4,550,340	$ 256,702
Derivative asset		1,736
Total Assets at Fair Value	4,550,340	258,438
Derivative liability		548,865
Total Liabilities at Fair Value	4,955,588	2,968,348
Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	256,650	71,581
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	1,591,409	2,347,902
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	3,107,529
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	4,550,340	256,702
Total Assets at Fair Value	4,550,340	256,702
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Derivative asset
Total Assets at Fair Value
Derivative liability
Total Liabilities at Fair Value
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset		1,736
Total Assets at Fair Value		1,736
Derivative liability		548,865
Total Liabilities at Fair Value	4,955,588	2,968,348
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	256,650	71,581
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	1,591,409	$ 2,347,902
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	$ 3,107,529

Fair Value Measurements (Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities) (Details)	9 Months Ended
	Sep. 30, 2013 USD ($)
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Balance at beginning of period	$ 1,736
Assets, Revaluation	(1,736)
Liabilities, Balance at beginning of period	2,968,348
Liabilities, Issues	19,358,108
Liabilities, Settlements	(42,144,409)
Liabilities, Revaluations	24,773,541
Liabilities, Balance at end of period	4,955,588
Warrants Issued December 29, 2008 [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Balance at beginning of period	71,581
Liabilities, Revaluations	185,069
Liabilities, Balance at end of period	256,650
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Balance at beginning of period	2,347,902
Liabilities, Settlements	(18,780,167)
Liabilities, Revaluations	18,023,674
Liabilities, Balance at end of period	1,591,409
Warrants Issued August 2013 [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Issues	19,358,108
Liabilities, Settlements	(10,535,592)
Liabilities, Revaluations	(5,714,987)
Liabilities, Balance at end of period	3,107,529
Derivative Liability [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Balance at beginning of period	548,865
Liabilities, Settlements	(12,828,650)
Liabilities, Revaluations	12,279,785
Derivative Asset [Member]
Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Assets, Balance at beginning of period	1,736
Assets, Revaluation	$ (1,736)

Description Of Business	9 Months Ended
Description Of Business	Sep. 30, 2013
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”). The Niobe ES system is the latest generation of the Niobe Robotic Magnetic Navigation System (“Niobe system”), which is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called the Odyssey Cinema solution, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The V-Sono ICE catheter manipulator has received U.S. clearance, and the V-Loop circular catheter manipulator is currently in clinical trials in order to obtain clearance by the U.S. Food and Drug Administration. Since our inception, we have generated significant losses. As of September 30, 2013 we had incurred cumulative net losses of approximately $449 million. In May 2011, the Company introduced the Niobe ES system. As of September 30, 2013, the Company had an installed base of 92 Niobe ES systems and has received positive feedback from the physicians at these sites. During the third quarter of 2011, the Company implemented a wide ranging plan to rebalance and reduce operating expenses by 15% to 20% on an annual run rate basis. During the year ended December 31, 2012, the Company reduced operating expenses by approximately $19 million or 31% over the prior year. We expect to incur additional losses throughout the remainder of 2013 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives.

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 30, 2013
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets On June 4, 2010, the Company entered into an agreement to issue 45,000 shares of its common stock to a consultant (the “Purchaser”) in exchange for intellectual property rights related to the Company’s products. The Company issued 20,000 shares upon execution of the agreement and has issued an aggregate of 25,000 shares in annual installments on the first three anniversaries of the agreement. There was no cash consideration paid for the securities. The securities were issued in consideration of the assignment to the Company of the Purchaser’s rights in certain intellectual property, including patent applications, in all inventions and discoveries in the Company’s business field (as defined in the agreement) that had been developed under various other agreements, which were terminated. The securities were sold by the Company in a private placement exempt from registration under Section 4(2) of the Securities Act of 1933 and Regulation D promulgated thereunder. There were no underwriters or placement agents involved in the transaction. As of September 30, 2013, the Company had total intangible assets, including those described above, of $3,665,000. Accumulated amortization at September 30, 2013, was $1,910,555.

Commitments And Contingencies	9 Months Ended
Commitments And Contingencies	Sep. 30, 2013
Commitments And Contingencies [Abstract]
Commitments And Contingencies	13. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company. In 2012, the Company entered into a letter of credit to support a commitment in the amount of approximately $0.1 million. This letter of credit is valid through 2015.

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2013
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On October 29, 2013, we filed a prospectus with the Securities Exchange Commission relating to a rights offering in which all stockholders and certain warrant holders of Stereotaxis, Inc. received subscription rights to purchase an aggregate of up to 6,315,953 shares of our common stock, par value $0.001 per share. All stockholders and certain warrant holders received subscription rights to purchase 1 share of common stock at a price of $3.00 per share for every 3 shares of stock that they held as of the record date of October 31, 2013. The NASDAQ Capital Market established Monday, November 4, 2013 as the “ex-rights” date for the rights offering. The ex-rights date is the date on which Stereotaxis’s common stock began to trade without the rights and the rights began to trade separately from the common stock. Between the record date and the ex-rights date, the rights traded together with the shares of common stock. The rights are listed on the NASDAQ Capital Market under the symbol “STXSR,” and will continue to be so listed until the expiration of the rights offering. The subscription rights will be exercisable until November 21, 2013 unless we choose to extend the rights offering beyond this date, which we do not currently expect to do.

Description Of Business (Details)	3 Months Ended	12 Months Ended
Description Of Business (Details)	Sep. 30, 2011	Dec. 31, 2012 USD ($)	Sep. 30, 2013 USD ($) item
Description Of Business [Line Items]
Cumulative losses incurred from inception		$ (384,645,873)	$ (449,441,255)
Installed base \| item			92
Reduction in operating expenses		$ 19,000,000
Annual plan to rebalance and reduce operating expenses, percentage		31.00%
Scenario, Forecast [Member] \| Maximum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage	20.00%
Scenario, Forecast [Member] \| Minimum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage	15.00%

Inventory (Schedule Of Inventory) (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Inventory [Abstract]
Raw materials	$ 2,897,716	$ 3,303,053
Work in process	432,759	65,546
Finished goods	1,528,411	1,802,281
Reserve for obsolescence	(120,854)	(72,639)
Total inventory	$ 4,738,032	$ 5,098,241

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 252,793	$ 330,756
Deferred cost of revenue	147,000	527,725
Derivative asset		1,736
Deferred financing costs	694,630	1,590,916
Deposits	823,989	1,040,934
Total prepaid expenses and other current assets	$ 1,918,412	$ 3,492,067

Property And Equipment (Schedule Of Property And Equipment) (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Gross property and equipment	$ 11,303,416	$ 11,393,834
Less: Accumulated depreciation	(9,884,096)	(9,251,911)
Net property and equipment	1,419,320	2,141,923
Equipment [Member]
Gross property and equipment	8,671,623	8,762,041
Equipment Held For Lease [Member]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Gross property and equipment	$ 2,328,381	$ 2,328,381

Intangible Assets (Details) - USD ($)	Jun. 04, 2010	Sep. 30, 2013
Intangible Assets [Abstract]
Total shares to exchange for intellectual property on agreement	45,000
Shares issued upon execution of agreement	20,000
Aggregate shares to be issued in annual installments on the first three anniversaries of the agreement	25,000
Total intangible assets, including those subject to execution of agreement		$ 3,665,000
Accumulated amortization		$ 1,910,555

Deferred Revenue (Schedule Of Deferred Revenue) (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 7,692,478	$ 9,980,098
Less: Long-term deferred revenue	(293,047)	(477,159)
Total current deferred revenue	7,399,431	9,502,939
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	1,570,771	3,206,641
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	420,723	558,227
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 5,700,984	$ 6,215,230

Stockholders' Equity (Summary Of The Restricted Shares Outstanding) (Details) - Restricted Stock [Member] - shares	Sep. 30, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	31,215	68,543
Time Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	7,675
Performance Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	23,540

Product Warranty Provisions (Schedule Of Accrued Warranty) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Product Warranty Provisions [Abstract]
Warranty accrual, beginning of the fiscal period	$ 653,473	$ 691,832
Warranty expense incurred	90,964	650,367
Payments made	(198,358)	(688,726)
Warranty accrual, end of the fiscal period	$ 546,079	$ 653,473

Commitments And Contingencies (Details) $ in Millions	Dec. 31, 2012 USD ($)
Commitments And Contingencies [Abstract]
Letter of credit	$ 0.1

Subsequent Events (Details)	1 Months Ended	9 Months Ended
Subsequent Events (Details)	Oct. 31, 2013	Sep. 30, 2013 $ / shares	Oct. 29, 2013 $ / item shares	Dec. 31, 2012 $ / shares
Subsequent Event [Line Items]
Common stock, par value \| $ / shares		$ 0.001		$ 0.001
Subsequent Event [Member]
Subsequent Event [Line Items]
Subsequent event date		Oct. 29, 2013
Aggregate number of shares issued upon conversion of subscription rights			6,315,953
Exercise price of Subscription right \| $ / item			3.00
Numbers of shares that can be purchased per share held			0.33
Record date of Subscription rights	Oct. 31, 2013
Date of "Ex-Rights"	Nov. 04, 2013
Subscription right exercisable expiration date	Nov. 21, 2013